Cancers affecting children, adolescents, and young adults present distinct biological, therapeutic, and survivorship challenges. This session focuses on improving diagnosis, treatment, supportive care, and long-term outcomes while addressing the unique needs of younger cancer populations.
Abstract Scope and Participation
Abstracts may cover childhood leukemia, pediatric solid tumors, adolescent and young adult cancers, cancer predisposition, molecular biology, immunotherapy, targeted therapy, treatment toxicity, survivorship, and late effects. Pediatric oncologists, researchers, nurses, psychologists, and allied professionals are encouraged to participate.
The landscape of pediatric oncology in India is undergoing a documented epidemiological transformation, with data-driven projections from the National Cancer Registry Programme (NCRP) forecasting a…
MicroRNAs are small non-coding RNA molecules that play a significant role in many physiological processes in the body, including posttranscriptional regulation of gene expression. Their expression in…
Background : Childhood acute lymphoblastic leukemia (ALL) is the most common pediatric cancer, yet significant inter-individual variability exists in response to its therapy. Genetic polymorphisms as…
Febrile neutropenia (FEN) is the most common life-threatening complication of childhood cancer. Early initiation of broad-spectrum intravenous antibiotics to patients has reduced the mortality of FEN…
RNA binding proteins (RBPs) are regulators of RNA metabolism and influence protein expression in various physiologic and pathologic conditions through regulation of RNA splicing, stability and…
Burkitt lymphoma is the most common non-Hodgkin lymphoma in children. Pediatric Burkitt lymphomas (pBLs) are characterized by fast tumor growth; therefore, rapid diagnosis and initiation of therapy…
Sessions are CPD-accredited; certificates issued to every registered delegate within two weeks of the conference.
Oral and poster slots for original Pediatric & AYA Oncology work, reviewed by the scientific committee.
Meet oncologists, cancer researchers, and clinical specialists from around the world across three days.
Accepted abstracts appear in the indexed conference proceedings with a citable DOI.
Plenary lectures from leading voices shaping Pediatric & AYA Oncology research and practice.
Attend in person in Singapore or join virtually — same programme, same certificate.
Oral and poster slots for your work — in person in Singapore or online. Not presenting? Attend as a delegate to learn from the field.
The Pediatric & AYA Oncology track is a dedicated stream within CIOC 2027 covering the latest research, clinical innovation, and best practice in Pediatric & AYA Oncology. It brings together researchers, educators, and practitioners for oral presentations, posters, and discussion.
Cancer researchers and clinicians, educators and students with an interest in Pediatric & AYA Oncology are all welcome — whether presenting or attending.
Yes. Submit an abstract for oral or poster presentation. All submissions are peer-reviewed by the scientific committee; accepted abstracts appear in the indexed proceedings.
Yes. CIOC 2027 is a hybrid conference — attend the Pediatric & AYA Oncology track in person in Singapore or join live online, with on-demand access afterward.
Singapore · March 15–17, 2027· Hybrid · in-person & virtual
Attend without presenting.
